Theranostics in Japan

Frankly, Japan is at the end of the line of current clinical theranostics such as

PRRT and PSMA. Many patients go abroad for PRRT and PSMA treatment. This

lamentable situation has been caused mainly by the strict regulations as well as the

limited number of isolation rooms available for these purposes in this country. But

despite this, Japanese scientists are developing several unique activities in theranostics,

including 211At[NaAt] for 131I radioiodine refractory thyroid cancer and meta-211Atastato-

benzyl guanidine (211At-MABG) for 131I-MIBG refractory pheochromocytoma/

paraganglioma, which are currently ready for investigator-initiated trial. There are

several other developments in this field. Such information is described in this short

article.

Keywords: 131I-MIBG, 211At[NaAt], 225Ac-fibroblast activation protein inhibitor (FAPI), 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM), Mmeta-211At-astato-benzylguanidine (211At-MABG).

Cite as

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Current Diabetes Reviews

Current Neurovascular Research

Current Respiratory Medicine Reviews

Current Pediatric Reviews

Infectious Disorders - Drug Targets

Current Stem Cell Research & Therapy

Endocrine, Metabolic & Immune Disorders - Drug Targets

Current Alzheimer Research

Current Aging Science

Andrology: Current and Future Developments

Male Infertility: An Integrative Manual of Western and Chinese Medicine

Awake Thoracic Surgery

The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy

Frontiers in Anti-infective Agents

The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo